“Oral mucositis represents a large area of unmet need and a substantial market opportunity. We, along with potential Pharma partners, feel Brilacidin—as a conveniently-administered oral rinse—is well-positioned possibly to emerge one day as a frontline, go-to treatment for this common, costly and debilitating side-effect of chemoradiation.”